Iovance says clear line of sight to profitability
Iovance Biotherapeutics says record Amtagvi sales underpin a “clear line of sight to profitability” as it prepares for year-end data and trial updates.
Iovance Biotherapeutics (IOVA) said on Tuesday it now has “a clear line of sight to profitability,” supported by record sales of its approved skin cancer drug Amtagvi as it gets ready for a run of data and trial updates scheduled through year-end. The company said it had a record Q2, with nearly $100 million in sales.